The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Tranilast directly targets NLRP 3 to treat inflammasome‐driven diseases
Open accessAbstract
The dysregulation of NLRP3 inflammasome can cause uncontrolled inflammation and drive the development of a wide variety of human diseases, but the medications targeting NLRP3 inflammasome are not available in clinic. Here, we show that tranilast (TR), an old anti‐allergic clinical drug, is a direct NLRP3 inhibitor. TR inhibits NLRP3 inflammasome activation in macrophages, but has no effects on AIM2 or NLRC4 inflammasome activation. Mechanismly, TR directly binds to the NACHT domain of NLRP3 and suppresses the assembly of NLRP3 inflammasome by blocking NLRP3 oligomerization. In vivo experiments show that TR has remarkable preventive or therapeutic effects on the mouse models of NLRP3 inflammasome‐related human diseases, including gouty arthritis, cryopyrin‐associated autoinflammatory syndromes, and type 2 diabetes. Furthermore, TR is active ex vivo for synovial fluid mononuclear cells from patients with gout. Thus, our study identifies the old drug TR as a direct NLRP3 inhibitor and provides a potentially practical pharmacological approach for treating NLRP3‐driven diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Self-citationGout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026 · cited 2×
“…disorders NLRP3 inflammasome has also been involved in chronic inflammation-associated complex diseases, including T2D (Martinon et al , 2006; Duewell et al , 2010; Masters et al , 2010; Zhou et al , 2010; Wen et al , 2011; Heneka et al , 2012; Lamkanfi & Dixit, 2012; Broderick et al ,…”
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Thioredoxin-interacting protein links oxidative stress to inflammasome activation
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010) · Nature Immunology · doi:10.1038/ni.1831 · Cited by 2,708
Self-citationNon-canonical inflammasome activation targets caspase-11
Kayagaki, N., Warming, S., Lamkanfi, M., Walle, L. V., Louie, S., Dong, J., Newton, K., Qu, Y., Liu, J., Heldens, S., et al. (2011) · Nature · doi:10.1038/nature10558 · Cited by 2,530
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Oh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W. J., Watkins, S. M., & Olefsky, J. M. (2010) · Cell · doi:10.1016/j.cell.2010.07.041 · Cited by 2,428
The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
Youm, Y.-H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., D'Agostino, D., Planavsky, N., Lupfer, C., Kanneganti, T. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3804 · Cited by 2,172
Muñoz-Planillo, R., Kuffa, P., Martínez-Colón, G., Smith, B. L., Rajendiran, T. M., & Núñez, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.05.016 · Cited by 2,147
Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling
Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M. T.-H., Brickey, W. J., & Ting, J. P.-Y. (2011) · Nature Immunology · doi:10.1038/ni.2022 · Cited by 1,698
The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases
Davis, B. K., Wen, H., & Ting, J. P.-Y. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101405 · Cited by 1,618
Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration
Pétrilli, V, Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402195 · Cited by 1,445 · cited 1×
“We then studied whether TR affected potassium efflux, which is an upstream signaling event of NLRP3 activation (Petrilli et al , 2007; Munoz-Planillo et al , 2013).”
Molecular mechanisms regulating NLRP3 inflammasome activation
Jo, E.-K., Kim, J. K., Shin, D.-M., & Sasakawa, C. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.95 · Cited by 1,378
Unified Polymerization Mechanism for the Assembly of ASC-Dependent Inflammasomes
Lu, A., Magupalli, V. G., Ruan, J., Yin, Q., Atianand, M. K., Vos, M. R., Schröder, G. F., Fitzgerald, K. A., Wu, H., & Egelman, E. H. (2014) · Cell · doi:10.1016/j.cell.2014.02.008 · Cited by 1,353
Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330 · cited 2×
“…and contribute to the development of human complex diseases, including gout, atherosclerosis, neurodegenerative diseases, and type 2 diabetes (T2D) (Martinon et al , 2006; Duewell et al , 2010; Masters et al , 2010; Zhou et al , 2010; Wen et al , 2011; Heneka et al , 2012; Lamkanfi & Dixit, 2012).”
NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux
He, Y., Zeng, M. Y., Yang, D., Motro, B., & Núñez, G. (2016) · Nature · doi:10.1038/nature16959 · Cited by 1,295
Hou, F., Sun, L., Zheng, H., Skaug, B., Jiang, Q.-X., & Chen, Z. J. (2011) · Cell · doi:10.1016/j.cell.2011.06.041 · Cited by 1,282
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
A Systematic Survey Identifies Prions and Illuminates Sequence Features of Prionogenic Proteins
Alberti, S., Halfmann, R., King, O., Kapila, A., & Lindquist, S. (2009) · Cell · doi:10.1016/j.cell.2009.02.044 · Cited by 968
Inflammasomes and Their Roles in Health and Disease
Lamkanfi, M., & Dixit, V. M. (2012) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101011-155745 · Cited by 935 · cited 2×
“…and contribute to the development of human complex diseases, including gout, atherosclerosis, neurodegenerative diseases, and type 2 diabetes (T2D) (Martinon et al , 2006; Duewell et al , 2010; Masters et al , 2010; Zhou et al , 2010; Wen et al , 2011; Heneka et al , 2012; Lamkanfi & Dixit, 2012).”
Glyburide inhibits the Cryopyrin/Nalp3 inflammasome
Lamkanfi, M., Mueller, J. L., Vitari, A. C., Misaghi, S., Fedorova, A., Deshayes, K., Lee, W. P., Hoffman, H. M., & Dixit, V. M. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200903124 · Cited by 820 · cited 1×
“…-nitrostyrene, glyburide, parthenolide, sulforaphane, isoliquiriti-genin, MCC950, b -hydroxybutyrate, flufenamic acid, and mefenamic acid (Lamkanfi et al , 2009; Juliana et al , 2010; Yan et al , 2013; Ahn et al , 2014; He et al , 2014; Honda et al , 2014; Coll et al , 2015; Youm et al ,…”
Yan, Y., Jiang, W., Spinetti, T., Tardivel, A., Castillo, R., Bourquin, C., Guarda, G., Tian, Z., Tschopp, J., & Zhou, R. (2013) · Immunity · doi:10.1016/j.immuni.2013.05.015 · Cited by 784 · cited 3×
“…sulforaphane, isoliquiriti-genin, MCC950, b -hydroxybutyrate, flufenamic acid, and mefenamic acid (Lamkanfi et al , 2009; Juliana et al , 2010; Yan et al , 2013; Ahn et al , 2014; He et al , 2014; Honda et al , 2014; Coll et al , 2015; Youm et al , 2015; Daniels et al , 2016; Yang et al ,…”
Self-citationNOD-Like Receptors: Role in Innate Immunity and Inflammatory Disease
Chen, G., Shaw, M. H., Kim, Y.-G., & Nuñez, G. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092239 · Cited by 772
Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders
Jiang, H., He, H., Chen, Y., Huang, W., Cheng, J., Ye, J., Wang, A., Tao, J., Wang, C., Liu, Q., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171419 · Cited by 748
Self-citationShi, H., Wang, Y., Li, X., Zhan, X., Tang, M., Fina, M., Su, L., Pratt, D., Bu, C. H., Hildebrand, S., et al. (2016) · Nature Immunology · doi:10.1038/ni.3333 · Cited by 745
A pilot study of IL-1 inhibition by anakinra in acute gout
So, A., De Smedt, T., Revaz, S., & Tschopp, J. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2143 · Cited by 727
Stienstra, R., Joosten, L. A. B., Koenen, T., van Tits, B., van Diepen, J. A., van den Berg, S. A. A., Rensen, P. C. N., Voshol, P. J., Fantuzzi, G., Hijmans, A., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.11.011 · Cited by 676
Anti-inflammatory Compounds Parthenolide and Bay 11-7082 Are Direct Inhibitors of the Inflammasome
Juliana, C., Fernandes-Alnemri, T., Wu, J., Datta, P., Solorzano, L., Yu, J.-W., Meng, R., Quong, A. A., Latz, E., Scott, C. P., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.082305 · Cited by 610
Dempsey, C., Rubio Araiz, A., Bryson, K. J., Finucane, O., Larkin, C., Mills, E. L., Robertson, A. A. B., Cooper, M. A., O'Neill, L. A. J., & Lynch, M. A. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.12.014 · Cited by 571 · cited 1×
“MCC950, flufenamic acid, and mefe-namic acid have been shown to delay the development of AD in mice model (Daniels et al , 2016; Dempsey et al , 2017).”
Duncan, J. A., Bergstralh, D. T., Wang, Y., Willingham, S. B., Ye, Z., Zimmermann, A. G., & Ting, J. P.-Y. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611496104 · Cited by 498
Protein–protein docking benchmark version 4.0
Hwang, H., Vreven, T., Janin, J., & Weng, Z. (2010) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.22830 · Cited by 476
Schmid-Burgk, J. L., Chauhan, D., Schmidt, T., Ebert, T. S., Reinhardt, J., Endl, E., & Hornung, V. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.c115.700492 · Cited by 456
Daniels, M. J. D., Rivers-Auty, J., Schilling, T., Spencer, N. G., Watremez, W., Fasolino, V., Booth, S. J., White, C. S., Baldwin, A. G., Freeman, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12504 · Cited by 442
Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite
Platten, M., Ho, P. P., Youssef, S., Fontoura, P., Garren, H., Hur, E. M., Gupta, R., Lee, L. Y., Kidd, B. A., Robinson, W. H., et al. (2005) · Science · doi:10.1126/science.1117634 · Cited by 425
Qaseem, A., Humphrey, L. L., Sweet, D. E., Starkey, M., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00011 · Cited by 400
ASC filament formation serves as a signal amplification mechanism for inflammasomes
Dick, M. S., Sborgi, L., Rühl, S., Hiller, S., & Broz, P. (2016) · Nature Communications · doi:10.1038/ncomms11929 · Cited by 394
Tang, T., Lang, X., Xu, C., Wang, X., Gong, T., Yang, Y., Cui, J., Bai, L., Wang, J., Jiang, W., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00227-x · Cited by 361
Self-citationCATERPILLERs, pyrin and hereditary immunological disorders
Ting, J. P.-Y., Kastner, D. L., & Hoffman, H. M. (2006) · Nature Reviews Immunology · doi:10.1038/nri1788 · Cited by 342
Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity
Brydges, S. D., Mueller, J. L., McGeough, M. D., Pena, C. A., Misaghi, A., Gandhi, C., Putnam, C. D., Boyle, D. L., Firestein, G. S., Horner, A. A., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.005 · Cited by 339
IL-1 Blockade in Autoinflammatory Syndromes
Jesus, A. A., & Goldbach-Mansky, R. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061512-150641 · Cited by 326
Tranilast: A review of its therapeutic applications
Darakhshan, S., & Pour, A. B. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2014.10.009 · Cited by 322
Predicting druggable binding sites at the protein–protein interface
Fuller, J. C., Burgoyne, N. J., & Jackson, R. M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.009 · Cited by 310
Terkeltaub, R., Sundy, J. S., Schumacher, H. R., Murphy, F., Bookbinder, S., Biedermann, S., Wu, R., Mellis, S., & Radin, A. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.108936 · Cited by 300
The Inflammasomes and Autoinflammatory Syndromes
Broderick, L., De Nardo, D., Franklin, B. S., Hoffman, H. M., & Latz, E. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040431 · Cited by 295
He, Y., Varadarajan, S., Muñoz-Planillo, R., Burberry, A., Nakamura, Y., & Núñez, G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.515080 · Cited by 268
Honda, H., Nagai, Y., Matsunaga, T., Okamoto, N., Watanabe, Y., Tsuneyama, K., Hayashi, H., Fujii, I., Ikutani, M., Hirai, Y., et al. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0114-005rr · Cited by 211
ZHANG, D., SPIELMANN, A., WANG, L., DING, G., HUANG, F., GU, Q., & SCHWARZ, W. (2012) · Physiological Research · doi:10.33549/physiolres.932053 · Cited by 199
Yang, G., Lee, H. E., & Lee, J. Y. (2016) · Scientific Reports · doi:10.1038/srep24399 · Cited by 170
Cocco, M., Pellegrini, C., Martínez-Banaclocha, H., Giorgis, M., Marini, E., Costale, A., Miglio, G., Fornai, M., Antonioli, L., López-Castejón, G., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01624 · Cited by 165
Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra
McGonagle, D. G., Tan, A. L., Shankaranarayana, S., Madden, J. M., Emery, P., & McDermott, M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.073759 · Cited by 146
Labbé, C. M., Laconde, G., Kuenemann, M. A., Villoutreix, B. O., & Sperandio, O. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.003 · Cited by 104
Mechanisms of joint damage in gout: evidence from cellular and imaging studies
McQueen, F. M., Chhana, A., & Dalbeth, N. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.207 · Cited by 93
Dimethyl sulfoxide inhibits NLRP3 inflammasome activation
Ahn, H., Kim, J., Jeung, E., & Lee, G. (2013) · Immunobiology · doi:10.1016/j.imbio.2013.11.003 · Cited by 84
Reber, L. L., Marichal, T., Sokolove, J. B., Starkl, P. M., Gaudenzio, N., Iwakura, Y., Karasuyama, H., Schwartz, L. B., Robinson, W. H., Tsai, M. M., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38747 · Cited by 81
Tranilast Inhibits Cytokine-Induced Nuclear Factor κB Activation in Vascular Endothelial Cells
Spiecker, M., Lorenz, I., Marx, N., & Darius, H. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.4.856 · Cited by 61
Chikaraishi, A., Hirahashi, J., Takase, O., Marumo, T., Hishikawa, K., Hayashi, M., & Saruta, T. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01215-8 · Cited by 46
Capper, E. A., Roshak, A., Bolognese, B. J., Podolin, P. L., Smith, T., DeWitt, D. L., Anderson, K. M., & Marshall, L. A. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39006-8 · Cited by 34
Cited by
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Swanson, K. V., Deng, M., & Ting, J. P.-Y. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0165-0 · Cited by 4,884
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
Gong, T., Liu, L., Jiang, W., & Zhou, R. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0215-7 · Cited by 1,672
Self-citationRecent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors
Yang, Y., Wang, H., Kouadir, M., Song, H., & Shi, F. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1413-8 · Cited by 1,269
Self-citationAn update on the regulatory mechanisms of NLRP3 inflammasome activation
Paik, S., Kim, J. K., Silwal, P., Sasakawa, C., & Jo, E.-K. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00670-3 · Cited by 892
Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
He, H., Jiang, H., Chen, Y., Ye, J., Wang, A., Wang, C., Liu, Q., Liang, G., Deng, X., Jiang, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04947-6 · Cited by 827
Self-citation
Metadata
- Authors
- Huang, Y., Jiang, H., Chen, Y., Wang, X., Yang, Y., Tao, J., Deng, X., Liang, G., Zhang, H., Jiang, W., & Zhou, R.
- Venue
- EMBO Molecular Medicine
- Published
- 2018-03-12
- Volume
- 10
- Issue
- 4
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2790572647
- Cited by
- 507
- References
- 60
- FWCI
- 13.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.